Quick Answer
Processa Pharmaceuticals, Inc. reported Cash and Equivalents of $5.54 million for fiscal year 2025.
Processa Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $5.54M | +364.8% |
| 2024 | $1.19M | -74.7% |
| 2023 | $4.71M | -27.6% |
| 2022 | $6.50M | -60.6% |
| 2021 | $16.50M | +7.0% |
| 2020 | $15.42M | +2129.3% |
| 2019 | $691.5K | -60.3% |
| 2018 | $1.74M | -38.9% |
| 2017 | $2.85M | +165.6% |
| 2016 | $1.07M | +51186.8% |
| 2015 | $2.1K | -90.2% |
| 2014 | $21.2K | -88.6% |
| 2013 | $186.9K | -81.7% |
| 2012 | $1.02M | -63.5% |
| 2011 | $2.79M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.31M | +118.2% | -9.1% |
| June 30, 2025 | $6.94M | +24.5% | +139.4% |
| March 31, 2025 | $2.90M | -67.5% | +143.2% |
| December 31, 2024 | $1.19M | -74.7% | -58.8% |
| September 30, 2024 | $2.89M | -57.9% | -48.1% |
| June 30, 2024 | $5.57M | -35.8% | -37.5% |
| March 31, 2024 | $8.92M | -17.0% | +89.5% |
| December 31, 2023 | $4.71M | -27.6% | -31.4% |
- Processa Pharmaceuticals, Inc. showed an increase of +364.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Processa Pharmaceuticals, Inc.’s cash and equivalents has grown by 98.1% (from $2.79 million to $5.54 million).
- The most recent figure is from Processa Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: